ER+/PR+/TFF3+/IMP3- immunoprofile distinguishes endometrioid from serous and clear cell carcinomas of the endometrium: A study of 401 cases

Paulette Mhawech-Fauceglia, Li Yan, Song Liu, Tanja Pejovic

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Aims: Differentiating endometrioid adenocarcinoma (EAC) from uterine serous carcinoma (USC) and clear cell carcinoma (CCC) of the endometrium can be challenging. We undertook an immunohistochemical study to address this issue. Methods and results: We evaluated 401 endometrial carcinomas cases by using four immunomarkers - oestrogen receptor (ER), progesterone receptor (PR), insulin-like growth factor II mRNA - binding protein 3 (IMP3), and intestinal trefoil factor 3 (TFF3)-on a tissue microarray. The cases included 311 EACs (G1, 146; G2, 104; and G3, 61), 69 USCs, and 21 CCCs. ER, PR and TFF3 were most frequently expressed in EACs (P+/PR+/TFF3+/IMP3- was the best marker combination associated with EAC [exact odds ratio (OR) 112; 95% confidence interval (CI) 19-∞; P+/PR+/TFF3+/IMP3- immunoprofile to be the best combination for confirming a diagnosis of endometrioid adenocarcinoma (exact OR 19.2; 95% CI 3-∞; P=0.0004). Conclusions: We recommend using an ER/PR/TFF3/IMP3 immunohistochemical panel in selected cases of endometrial carcinoma where the differential diagnosis is challenging.

Original languageEnglish (US)
Pages (from-to)976-985
Number of pages10
JournalHistopathology
Volume62
Issue number7
DOIs
StatePublished - Jun 2013

Fingerprint

Progesterone Receptors
Endometrial Neoplasms
Carrier Proteins
Endometrioid Carcinoma
Messenger RNA
Odds Ratio
Confidence Intervals
Insulin-Like Growth Factor II
Estrogen Receptors
Trefoil Factor-3
Differential Diagnosis
Carcinoma

Keywords

  • Differential diagnosis
  • Endometrial adenocarcinoma
  • Immunomarkers
  • Tissue microarray

ASJC Scopus subject areas

  • Histology
  • Pathology and Forensic Medicine

Cite this

ER+/PR+/TFF3+/IMP3- immunoprofile distinguishes endometrioid from serous and clear cell carcinomas of the endometrium : A study of 401 cases. / Mhawech-Fauceglia, Paulette; Yan, Li; Liu, Song; Pejovic, Tanja.

In: Histopathology, Vol. 62, No. 7, 06.2013, p. 976-985.

Research output: Contribution to journalArticle

@article{62d20559255b44e19ab19621d6c67013,
title = "ER+/PR+/TFF3+/IMP3- immunoprofile distinguishes endometrioid from serous and clear cell carcinomas of the endometrium: A study of 401 cases",
abstract = "Aims: Differentiating endometrioid adenocarcinoma (EAC) from uterine serous carcinoma (USC) and clear cell carcinoma (CCC) of the endometrium can be challenging. We undertook an immunohistochemical study to address this issue. Methods and results: We evaluated 401 endometrial carcinomas cases by using four immunomarkers - oestrogen receptor (ER), progesterone receptor (PR), insulin-like growth factor II mRNA - binding protein 3 (IMP3), and intestinal trefoil factor 3 (TFF3)-on a tissue microarray. The cases included 311 EACs (G1, 146; G2, 104; and G3, 61), 69 USCs, and 21 CCCs. ER, PR and TFF3 were most frequently expressed in EACs (P+/PR+/TFF3+/IMP3- was the best marker combination associated with EAC [exact odds ratio (OR) 112; 95{\%} confidence interval (CI) 19-∞; P+/PR+/TFF3+/IMP3- immunoprofile to be the best combination for confirming a diagnosis of endometrioid adenocarcinoma (exact OR 19.2; 95{\%} CI 3-∞; P=0.0004). Conclusions: We recommend using an ER/PR/TFF3/IMP3 immunohistochemical panel in selected cases of endometrial carcinoma where the differential diagnosis is challenging.",
keywords = "Differential diagnosis, Endometrial adenocarcinoma, Immunomarkers, Tissue microarray",
author = "Paulette Mhawech-Fauceglia and Li Yan and Song Liu and Tanja Pejovic",
year = "2013",
month = "6",
doi = "10.1111/his.12096",
language = "English (US)",
volume = "62",
pages = "976--985",
journal = "Histopathology",
issn = "0309-0167",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - ER+/PR+/TFF3+/IMP3- immunoprofile distinguishes endometrioid from serous and clear cell carcinomas of the endometrium

T2 - A study of 401 cases

AU - Mhawech-Fauceglia, Paulette

AU - Yan, Li

AU - Liu, Song

AU - Pejovic, Tanja

PY - 2013/6

Y1 - 2013/6

N2 - Aims: Differentiating endometrioid adenocarcinoma (EAC) from uterine serous carcinoma (USC) and clear cell carcinoma (CCC) of the endometrium can be challenging. We undertook an immunohistochemical study to address this issue. Methods and results: We evaluated 401 endometrial carcinomas cases by using four immunomarkers - oestrogen receptor (ER), progesterone receptor (PR), insulin-like growth factor II mRNA - binding protein 3 (IMP3), and intestinal trefoil factor 3 (TFF3)-on a tissue microarray. The cases included 311 EACs (G1, 146; G2, 104; and G3, 61), 69 USCs, and 21 CCCs. ER, PR and TFF3 were most frequently expressed in EACs (P+/PR+/TFF3+/IMP3- was the best marker combination associated with EAC [exact odds ratio (OR) 112; 95% confidence interval (CI) 19-∞; P+/PR+/TFF3+/IMP3- immunoprofile to be the best combination for confirming a diagnosis of endometrioid adenocarcinoma (exact OR 19.2; 95% CI 3-∞; P=0.0004). Conclusions: We recommend using an ER/PR/TFF3/IMP3 immunohistochemical panel in selected cases of endometrial carcinoma where the differential diagnosis is challenging.

AB - Aims: Differentiating endometrioid adenocarcinoma (EAC) from uterine serous carcinoma (USC) and clear cell carcinoma (CCC) of the endometrium can be challenging. We undertook an immunohistochemical study to address this issue. Methods and results: We evaluated 401 endometrial carcinomas cases by using four immunomarkers - oestrogen receptor (ER), progesterone receptor (PR), insulin-like growth factor II mRNA - binding protein 3 (IMP3), and intestinal trefoil factor 3 (TFF3)-on a tissue microarray. The cases included 311 EACs (G1, 146; G2, 104; and G3, 61), 69 USCs, and 21 CCCs. ER, PR and TFF3 were most frequently expressed in EACs (P+/PR+/TFF3+/IMP3- was the best marker combination associated with EAC [exact odds ratio (OR) 112; 95% confidence interval (CI) 19-∞; P+/PR+/TFF3+/IMP3- immunoprofile to be the best combination for confirming a diagnosis of endometrioid adenocarcinoma (exact OR 19.2; 95% CI 3-∞; P=0.0004). Conclusions: We recommend using an ER/PR/TFF3/IMP3 immunohistochemical panel in selected cases of endometrial carcinoma where the differential diagnosis is challenging.

KW - Differential diagnosis

KW - Endometrial adenocarcinoma

KW - Immunomarkers

KW - Tissue microarray

UR - http://www.scopus.com/inward/record.url?scp=84877924765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877924765&partnerID=8YFLogxK

U2 - 10.1111/his.12096

DO - 10.1111/his.12096

M3 - Article

C2 - 23570281

AN - SCOPUS:84877924765

VL - 62

SP - 976

EP - 985

JO - Histopathology

JF - Histopathology

SN - 0309-0167

IS - 7

ER -